Background/Objectives: Beta adrenergic signaling has been implicated in cancer progression, leading to interest in repurposing beta blockers (BBs) as adjunctive anti-cancer agents. However, clinical findings are inconsistent. This systematic review and meta-analysis evaluates the association between BB use and survival outcomes in cancer patients. Methods: A systematic search of OVID Medline, EMBASE, and CENTRAL was conducted through 13 September 2023, for studies comparing survival outcomes in solid tumor patients using BBs versus non-users. Eligible studies reported hazard ratios (HRs) for overall survival (OS), progression-free survival (PFS), or cancer-specific survival (CSS). Perioperative studies and those without BB-specific HRs were excluded. Data extraction and quality assessment were performed in duplicate using ROBINS-I. A random-effects model was used, with heterogeneity assessed by the I2 statistic. Results: Seventy-nine studies (492,381 patients) met the inclusion criteria; 2.5% were prospective. The most frequently studied cancers were breast (n = 33), ovarian (n = 30), and colorectal (n = 28). BB use was associated with improved PFS (HR 0.78, 95% CI: 0.66–0.92, I2 = 79.8%), with significance maintained after excluding high-bias studies (HR 0.74, 95% CI: 0.61–0.91, I2 = 36.6%). No significant associations were observed for OS (HR 0.99, 95% CI: 0.94–1.04, I2 = 84.9%) or CSS (HR 0.95, 95% CI: 0.91–1.00, I2 = 77.4%). Conclusions: BB use may be associated with longer PFS in cancer patients, but findings are limited by study design and heterogeneity; high-quality prospective studies are needed.
Small-cell neuroendocrine carcinoma of the cervix (SCNECC) is a rare cancer with poor prognosis, with limited data to guide its treatment. The objective of this study was to evaluate practice patterns in the management of SCNECC. A 23-question online survey on management of SCNECC was disseminated to Canadian gynecologic oncologists (GO), radiation oncologists (RO) and medical oncologists (MO). In total, 34 practitioners from eight provinces responded, including 17 GO, 13 RO and four MO. During staging and diagnosis, 74% of respondents used a trimodality imaging approach, and 85% tested for neuroendocrine markers. In early-stage (1A1-1B2) SCNECC, 87% of practitioners used a surgical-based approach with various adjuvant and neoadjuvant treatments. In locally advanced (1B3-IVA) SCNECC, 53% favored primary chemoradiation, with cisplatin and etoposide, with the remainder using surgical or radiation-based approaches. In metastatic and recurrent SCNECC, the most common first-line regimen was etoposide and platinum, and 63% of practitioners considered clinical trials in the first line setting or beyond. This survey highlights diverse practice patterns in the treatment of SCNECC. Interdisciplinary input is crucial to individualizing multimodality treatment, and there is a need for prospective trials and intergroup collaboration to define the optimal approach towards managing this rare cancer type.
Adolescents and young adults (AYA) assigned female at birth with cancer face significant sexual health challenges, yet accessible, age-appropriate educational tools remain limited. This study evaluated a 13 min whiteboard video designed to improve sexual health knowledge. Female AYA patients aged 15–39 years across Canada completed pre- and post-video surveys assessing knowledge, attitudes, and satisfaction. The video’s understandability and actionability were measured using the Patient Education Materials Assessment Tool for Audiovisual Materials (PEMAT-A/V), and readability was assessed using six standard metrics. Quantitative analyses included paired t-tests and regression modeling; qualitative responses were thematically coded. Ninety participants completed the study. Knowledge scores increased by 19.5% (95% CI, 14–24%; p < 0.001, Cohen’s d = 0.89) following the video. Greater gains were observed among participants with a high school education or less (p = 0.040), while younger participants tended to show larger improvements. The video received average PEMAT-A/V scores of 96% for understandability and 94% for actionability. Most participants (89%) found it helpful for learning about sexual health and would recommend the video to peers, though suggested improvements included shorter length, enhanced visuals, and more age-specific content. Nearly half reported never discussing sexual health with providers. These findings support the feasibility of whiteboard video as an effective, scalable tool to address sexual health in oncology care.